Literature DB >> 30295837

Mechanisms of high-level ceftolozane/tazobactam resistance in Pseudomonas aeruginosa from a severely neutropenic patient and treatment success from synergy with tobramycin.

Wonhee So1, James Shurko2,3, Ralph Galega2,3, Rod Quilitz1, John N Greene1, Grace C Lee2,3.   

Abstract

Entities:  

Year:  2019        PMID： 30295837     DOI： 10.1093/jac/dky393

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  14 in total

Review 1.  Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress".

Authors:  Krisztina M Papp-Wallace; Andrew R Mack; Magdalena A Taracila; Robert A Bonomo
Journal:  Infect Dis Clin North Am       Date:  2020-09-30       Impact factor: 5.982

2.  Comparative Evaluation of the In Vitro Activities of WCK 5222 (Cefepime-Zidebactam) and Combination Antibiotic Therapies against Carbapenem-Resistant Pseudomonas aeruginosa.

Authors:  Elias M Mullane; Lindsay M Avery; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

Review 3.  Recognizing and Overcoming Resistance to New Beta-Lactam/Beta-Lactamase Inhibitor Combinations.

Authors:  Stephanie Ho; Lynn Nguyen; Trang Trinh; Conan MacDougall
Journal:  Curr Infect Dis Rep       Date:  2019-09-09       Impact factor: 3.725

Review 4.  New β-Lactam-β-Lactamase Inhibitor Combinations.

Authors:  Dafna Yahav; Christian G Giske; Alise Grāmatniece; Henrietta Abodakpi; Vincent H Tam; Leonard Leibovici
Journal:  Clin Microbiol Rev       Date:  2020-11-11       Impact factor: 26.132

5.  In Vitro Susceptibility of Typhoidal, Nontyphoidal, and Extended-Spectrum-β-Lactamase-Producing Salmonella to Ceftolozane/Tazobactam.

Authors:  Jade L L Teng; Elaine Chan; Asher C H Dai; Gillian Ng; Tsz Tuen Li; Christopher Lai; Alan K L Wu; Susanna K P Lau; Patrick C Y Woo
Journal:  Antimicrob Agents Chemother       Date:  2021-10-18       Impact factor: 5.938

6.  Mechanisms of Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa: Results of the GERPA Multicenter Study.

Authors:  Damien Fournier; Romain Carrière; Maxime Bour; Emilie Grisot; Pauline Triponney; Cédric Muller; Jérôme Lemoine; Katy Jeannot; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

7.  A Dimer, but Not Monomer, of Tobramycin Potentiates Ceftolozane against Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa and Delays Resistance Development.

Authors:  Temilolu Idowu; George G Zhanel; Frank Schweizer
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

Review 8.  Ceftazidime/Avibactam and Ceftolozane/Tazobactam for Multidrug-Resistant Gram Negatives in Patients with Hematological Malignancies: Current Experiences.

Authors:  Marianna Criscuolo; Enrico Maria Trecarichi
Journal:  Antibiotics (Basel)       Date:  2020-02-03

Review 9.  Understanding and Managing Sepsis in Patients With Cancer in the Era of Antimicrobial Resistance.

Authors:  Carlota Gudiol; Adaia Albasanz-Puig; Guillermo Cuervo; Jordi Carratalà
Journal:  Front Med (Lausanne)       Date:  2021-03-31

10.  Real-world use of ceftolozane/tazobactam: a systematic literature review.

Authors:  Laura Puzniak; Ryan Dillon; Thomas Palmer; Hannah Collings; Ashley Enstone
Journal:  Antimicrob Resist Infect Control       Date:  2021-04-08       Impact factor: 4.887
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.